5%+ stake

Pasithea Therapeutics (KTTA): Opaleye Management Inc. cut its KTTA stake below 5% (0%) 0.0%

Opaleye Management Inc. cut its KTTA stake below 5% (0%).

0.0%
Stake
Stake as of
Sep 30, 2026
Filed
Nov 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously reported, on February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance…”

What came next

  1. Nov 6, 20265% stakeOpaleye Management Inc. reported a passive stake (13G)
  2. Nov 13, 2026Insider10% owner purchased ~$104K of KTTA shares in the open market
  3. Nov 16, 20265% stakeVivo Opportunity Fund Holdings, L.P. reported a passive stake (13G) of 10.0%
  4. Nov 16, 20265% stakeStonepine Capital Management, LLC reported a passive stake (13G) of 8.3%
  5. Nov 16, 20265% stakeAmeriprise Financial, Inc. reported a passive stake (13G) of 4.1%
  6. Nov 16, 2026Insider · Largest insider buy since 202210% owner purchased ~$291K of KTTA shares in the open market
  7. Nov 17, 2026Insider · Largest insider buy since 202210% owner purchased ~$411K of KTTA shares in the open market
View the official recordSEC Schedule 13G

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Pasithea Therapeutics

For Pasithea Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KTTA page.

How this filing works

Explore the data

Common questions

What does this filing report about Pasithea Therapeutics (KTTA) stock?

Opaleye Management Inc. cut its KTTA stake below 5% (0%). Of the company, Schedule 13G (passive).

When did it happen, and when was it made public?

Stake as of: Sep 30, 2026. Filed: Nov 6, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Pasithea Therapeutics recently?

For Pasithea Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the KTTA page.

Does this mean KTTA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Pasithea Therapeutics

Everything OQRO holds on this company is on its KTTA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data